Phase 3 trial shows lanadelumab to be effective in reducing hereditary angioedema attacks

November 27, 2018, Massachusetts General Hospital

A phase 3 clinical trial led by a Massachusetts General Hospital (MGH) physician, finds that injections of the monoclonal antibody drug lanadelumab reduced attacks of hereditary angioedema (HAE)—a rare, potentially life-threatening disorder. The results of this trial, which are being published in the November 27 issue of JAMA, supported the FDA approval of lanadelumab for HAE earlier this year.

"Our study and the subsequent FDA approval of lanadelumab have given patients with HAE an important, novel option for ," says Aleena Banerji, MD, of the MGH Division of Rheumatology, Allergy and Immunology, lead author of the JAMA report and principal investigator of the trial. "Previously the only approved were oral androgens, which have significant side effects, and either intravenous or subcutaneous C1 inhibitor administration, which needs to be given twice a week. Subcutaneous lanadelumab, given once every two or every four weeks, is much easier for patients with an equally high level of efficacy."

Caused by genetic mutations associated with either decreased levels of C1 inhibitor protein—an enzyme that inhibits the kallikrein-kinin pathway, a group of proteins involved with inflammation, blood pressure control and other functions—or dysfunctional C1 inhibitor, HAE is characterized by elevated levels of bradykinin, a protein that induces leakage of fluids from the blood into tissues. The resultant swelling can significantly impact patients' daily activities, and swelling that involves the airway can be life-threatening. Lanadelumab interferes with the process leading to bradykinin generation by inhibiting the action of active plasma kallikrein, an enzyme that induces the protein's release. Banerji also led a phase 1b trial, published in the February 23, 2017, New England Journal of Medicine, finding that lanadelumab injections safely reduced HAE attacks in a group of 37 patients.

The 3 trial—conducted at 41 sites in the U.S., Canada, Europe and Jordan—enrolled 125 , 113 of whom completed the 26-week study. In the randomized, double-blinded trial, three groups received subcutaneous lanadelumab injections—either 150 mg every 4 weeks, 300 mg every 4 weeks, or 300 mg every 2 weeks—and a fourth received placebo injections. Trial results were based on the number of attacks during the study period, the severity of attacks and other factors.

All three of the lanadelumab treatment dosages were better than placebo in reducing the number of attacks. During the study period, the lanadelumab treatment groups averaged from 0.26 to 0.53 attacks over 26 weeks, compared with an average of 1.97 attacks among the placebo group. Significantly more participants receiving lanadelumab than those in the placebo group were attack free throughout the period—31 to 44 percent compared with 2.4 percent—and reductions were seen in the numbers of moderate attacks, severe attacks and attacks requiring acute treatment. Participants receiving the active drug also reported significant improvements in their quality of life.

Reported adverse events primarily related to pain at the injection site, which the authors note probably relates to the study protocol that required participants to receive two injections in the same arm at each study visit. At the end of the study period, 109 participants entered an open-label trial extension, receiving 300 mg doses every 2 weeks. "All participants in our trial—including those in the placebo group—can complete the open-label trial, which is anticipated to be finished in mid-2019," says Banerji, who is an associate professor of Medicine at Harvard Medical School.

Explore further: Clinical trial supports use of novel preventive therapy for dangerous swelling disorder

More information: Aleena Banerji et al, Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks, JAMA (2018). DOI: 10.1001/jama.2018.16773

Related Stories

Clinical trial supports use of novel preventive therapy for dangerous swelling disorder

February 27, 2017
clinical trial for a new drug to prevent attacks of hereditary angioedema (HAE) - a rare disorder characterized by recurrent swelling of tissues in the face, hands, gastrointestinal tract and airway - has had promising results. ...

In rare disorder, novel agent stops swelling before it starts

February 22, 2017
An early-stage clinical trial has found that, compared to a placebo, a novel medication significantly reduces potentially life-threatening episodes of swelling of the airway as well as the hands, feet, and abdomen of patients ...

C1 inhibitor use reduces attacks in hereditary angioedema

March 23, 2017
(HealthDay)—Prophylactic use of the subcutaneous C1 inhibitor CSL830 is associated with a reduction in the frequency of acute attacks in patients with hereditary angioedema, according to a study published in the March 23 ...

Phase 3 trial confirms superiority of tocilizumab to steroids for giant cell arteritis

July 26, 2017
A phase 3 clinical trial has confirmed that regular treatment with tocilizumab, an inhibitor of interleukin-6, successfully reduced both symptoms of and the need for high-dose steroid treatment for giant cell arteritis, the ...

New hope for rare disorder

July 26, 2018
Hereditary angioedema is a chronic disorder that can sometimes be life-threatening. Now, a new drug therapy has been successfully tested in an international study headed by the University Hospital Frankfurt.

Recommended for you

HIV vaccine protects non-human primates from infection

December 14, 2018
For more than 20 years, scientists at Scripps Research have chipped away at the challenges of designing an HIV vaccine. Now new research, published in Immunity, shows that their experimental vaccine strategy works in non-human ...

RNA processing and antiviral immunity

December 14, 2018
The RIG-I like receptors (RLRs) are intracellular enzyme sentries that detect viral infection and initiate a first line of antiviral defense. The cellular molecules that activate RLRs in vivo are not clear.

The 'greying' of T cells: Scientists pinpoint metabolic pathway behind age-related immunity loss

December 13, 2018
The elderly suffer more serious complications from infections and benefit less from vaccination than the general population. Scientists have long known that a weakened immune system is to blame but the exact mechanisms behind ...

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

Drug targets for Ebola, Dengue, and Zika viruses found in lab study

December 13, 2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes ...

Urbanisation and air travel leading to growing risk of pandemic

December 13, 2018
Increased arrivals by air and urbanisation are the two main factors leading to a growing vulnerability to pandemics in our cities, a University of Sydney research team has found.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.